US$27,000,000,000 BRIDGE LOAN CREDIT AGREEMENT dated as of September 25, 2015 among TEVA PHARMACEUTICAL INDUSTRIES LIMITED, as Parent, TEVA PHARMACEUTICALS USA, INC., TEVA CAPITAL SERVICES SWITZERLAND GMBH and TEVA PHARMACEUTICAL FINANCE NETHERLANDS...Bridge Loan Credit Agreement • September 29th, 2015 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations • New York
This Bridge Loan Credit Agreement (this “Agreement” or “Credit Agreement”), dated as of September 25, 2015, is among TEVA PHARMACEUTICAL INDUSTRIES LIMITED, an Israeli company registered under no 52-0013-954, the registered address of which is at Har Hozvim, Jerusalem, ISRAEL (the “Company” or “Parent”), upon accession or signature hereof, TEVA PHARMACEUTICALS USA, INC., a Delaware corporation, the principal office of which is at 1090 Horsham Road, North Wales, Pennsylvania, United States of America (“Teva USA” or the “US Borrower”), upon accession or signature hereof, TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V., a besloten vennootschap incorporated under the laws of the Netherlands, with its official seat (statutaire zetel) in Amsterdam, the Netherlands and the registered address of which is Piet Heinkade 107, 1019GM Amsterdam, registered with the Dutch trade register under number 855546876 (the “Dutch Borrower”), upon accession or signature hereof, TEVA CAPITAL SERVICES SWITZERL
